


CLAIMS

1. A compound of formula (I):



(I)

and pharmaceutically acceptable derivatives thereof,
wherein:

A and B are independently E, (C₁-C₁₀)-straight or branched alkyl, (C₂-C₁₀)-straight or branched alkenyl or alkynyl, or (C₅-C₇)-cycloalkyl or cycloalkenyl; wherein 1 or 2 hydrogen atoms in said alkyl, alkenyl or alkynyl are optionally and independently replaced with E, (C₅-C₇)-cycloalkyl or cycloalkenyl; and wherein 1 to 2 methylene (-CH₂-) groups in said alkyl, alkenyl, or alkynyl groups are optionally and independently replaced by -O-, -S-, -S(O)-, -S(O)₂-, =N-, -N= or -N(R³)-;

or B is hydrogen;

wherein R³ is selected from hydrogen, (C₁-C₄)-straight or branched alkyl, (C₃-C₄)-straight or branched alkenyl or alkynyl, or (C₁-C₄) bridging alkyl, wherein said bridge is formed between the nitrogen atom to which said R³ is bound and any carbon atom of said alkyl, alkenyl or alkynyl to form a ring, and wherein said ring is optionally benzofused;

wherein E is a saturated, partially saturated or unsaturated, or aromatic monocyclic or bicyclic ring system, wherein each ring comprises 5 to 7 ring atoms

Sub A 10039898-010302

independently selected from C, N, O or S; and wherein no more than 4 ring atoms are selected from N, O or S;

wherein 1 to 4 hydrogen atoms in E are optionally and independently replaced with halogen, hydroxyl, hydroxymethyl, nitro, SO₃H, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl, O-[(C₁-C₆)-straight or branched alkyl], O-[(C₃-C₆)-straight or branched alkenyl], (CH₂)_n-N(R⁴)(R⁵), (CH₂)_n-NH(R⁴)-(CH₂)_n-Z, (CH₂)_n-N(R⁴-(CH₂)_n-Z)(R⁵-(CH₂)_n-Z), (CH₂)_n-Z, O-(CH₂)_n-Z, (CH₂)_n-O-Z, S-(CH₂)_n-Z, CH=CH-Z, 1,2-methylenedioxy, C(O)OH, C(O)O-[(C₁-C₆)-straight or branched alkyl], C(O)O-(CH₂)_n-Z or C(O)-N(R⁴)(R⁵);

wherein each of R⁴ and R⁵ are independently hydrogen, (C₁-C₆)-straight or branched alkyl, (C₃-C₅)-straight or branched alkenyl, or wherein R⁴ and R⁵, when bound to the same nitrogen atom, are taken together with the nitrogen atom to form a 5 or 6 membered ring, wherein said ring optionally contains 1 to 3 additional heteroatoms independently selected from N, O or S; wherein said alkyl, alkenyl or alkynyl groups in R₄ and R₅ are optionally substituted with Z.

each n is independently 0 to 4;

each Z is independently selected from a saturated, partially saturated or unsaturated, monocyclic or bicyclic ring system, wherein each ring comprises 5 to 7 ring atoms independently selected from C, N, O or S; and wherein no more than 4 ring atoms are selected from N, O or S;

wherein 1 to 4 hydrogen atoms in Z are optionally and independently replaced with halo, hydroxy, nitro, cyano, C(O)OH, (C₁-C₃)-straight or branched alkyl,

Sub
B1

20039898.010302

O-(C₁-C₃)-straight or branched alkyl,
C(O)O-[(C₁-C₃)-straight or branched alkyl], amino,
NH[(C₁-C₃)-straight or branched alkyl], or
N-[(C₁-C₃)-straight or branched alkyl]₂;

5 K¹ is selected from hydrogen, E, (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl or alkynyl, wherein 1 to 2 hydrogen atoms in said alkyl, alkenyl or alkynyl is optionally and independently replaced with E;

10 wherein K¹ is optionally substituted with up to 3 substituents selected from halogen, OH, O-(C₁-C₆)-alkyl, O-(CH₂)_n-Z, NO₂, CO₂H, C(O)-O-(C₁-C₆)-alkyl, C(O)NR⁴R⁵, NR⁴R⁵ and (CH₂)_n-Z;

J and K, taken together with the two nitrogens that
15 they are attached to, form a 5-7 membered saturated or unsaturated heterocyclic ring, wherein 1 to 2 hydrogen atoms in said ring are optionally and independently replaced with (C₁-C₆)-straight or branched alkyl, (C₂-C₆)-straight or branched alkenyl or alkynyl, oxo,
20 hydroxyl or Z; and wherein any -CH₂- group in said heterocyclic ring is optionally and independently replaced by -O-, -S-, -S(O)-, -S(O)₂-, or -N(R³)-; and wherein said ring is optionally fused with E;

G, when present, is -S(O)₂-, -C(O)-, -S(O)₂-Y-,
25 -C(O)-Y-, -C(O)-C(O)-, or -C(O)-C(O)-Y-;

Y is oxygen, or N(R⁶);

wherein R⁶ is hydrogen, E, (C₁-C₆)-straight or branched alkyl, (C₃-C₆)-straight or branched alkenyl or alkynyl; or wherein R⁶ and D are taken together with the
30 atoms to which they are bound to form a 5 to 7 membered ring system wherein said ring optionally contains 1 to 3 additional heteroatoms independently selected from O, S,

Sub
B1

2020070-86868007

N, NH, SO, or SO₂; and wherein said ring is optionally benzofused;

Sub B1
D is hydrogen, (C₁-C₇)-straight or branched alkyl, (C₂-C₇)-straight or branched alkenyl or alkynyl, 5 (C₅-C₇)-cycloalkyl or cycloalkenyl optionally substituted with (C₁-C₆)-straight or branched alkyl or (C₂-C₇)-straight or branched alkenyl or alkynyl, [(C₁-C₇)-alkyl]-E, [(C₂-C₇)-alkenyl or alkynyl]-E, or E;

wherein 1 to 2 of the CH₂ groups of said alkyl, 10 alkenyl or alkynyl chains in D is optionally replaced by -O-, -S-, -S(O)-, -S(O₂)-, or -N(R³);

provided that when J is hydrogen or G is selected from -S(O)₂-, -C(O)C(O)-, -SO₂-Y, or -C(O)-Y, or -C(O)C(O)-Y, wherein Y = O; then D is not hydrogen;

15 x = 0 or 1; and

X = 0 or two hydrogens attached to ring carbon.

2. The compound according to claim 1, wherein:

20 each of A and B is independently selected from -CH₂-CH₂-E or -CH₂-CH₂-CH₂-E; and

E is a monocyclic or bicyclic aromatic ring system, wherein said ring comprises 5-7 ring atoms independently selected from C, N, O or S, and wherein 1 to 4 ring atoms 25 are independently selected from N, O or S;

wherein 1 to 4 hydrogen atoms in E are optionally and independently replaced with halogen, hydroxyl, hydroxymethyl, nitro, SO₃H, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-straight or branched alkyl, 30 (C₂-C₆)-straight or branched alkenyl, O-[(C₁-C₆)-straight or branched alkyl], O-[(C₃-C₆)-straight or branched alkenyl], (CH₂)_n-N(R⁴)(R⁵), (CH₂)_n-NH(R⁴)-(CH₂)_n-Z,

Sub
B¹

$(CH_2)_n-N(R^4-(CH_2)_n-Z)(R^5-(CH_2)_n-Z)$, $(CH_2)_n-Z$, $O-(CH_2)_n-Z$,
 $(CH_2)_n-O-Z$, $S-(CH_2)_n-Z$, $CH=CH-Z$, 1,2-methylenedioxy,
 $C(O)OH$, or $C(O)-N(R^4)(R^5)$.

5 3. The compound according to claim 1 or 2,
wherein D is an aromatic monocyclic or bicyclic ring
system, wherein each ring comprises 5 to 7 ring atoms
independently selected from C, N, O or S; and wherein no
more than 4 ring atoms are selected from N, O or S.

10

4. The compound according to claim 3, wherein
D is substituted phenyl.

Sub
B¹

15 5. The compound according to claim 1, wherein
K¹ is selected from E, (C₁-C₆)-straight or branched alkyl,
(C₂-C₆)-straight or branched alkenyl or alkynyl, wherein 1
to 2 hydrogen atoms in said alkyl, alkenyl or alkynyl is
optionally and independently replaced with E;

wherein K¹ is substituted with up to 3
20 substituents selected from halogen, OH, O-(C₁-C₆)-alkyl,
O-(CH₂)_n-Z, NO₂, CO₂H, C(O)-O-(C₁-C₆)-alkyl, C(O)NR⁴R⁵,
NR⁴R⁵ and (CH₂)_n-Z.

25 6. The compound according to claim 2, wherein
each of A and B is independently selected from -CH₂-CH₂-E
or -CH₂-CH₂-CH₂-E; and
E is pyridyl.

30 7. A composition comprising a compound
according to claim 1 and a carrier.

8. The composition according to claim 7,

further comprising a neurotrophic factor.

9. The composition according to claim 8,
wherein said neurotrophic factor is selected from nerve
5 growth factor (NGF), insulin-like growth factor (IGF-1)
and its active truncated derivatives such as gIGF-1 and
Des(1-3)IGF-I, acidic and basic fibroblast growth factor
(aFGF and bFGF, respectively), platelet-derived growth
factors (PDGF), brain-derived neurotrophic factor (BDNF),
10 ciliary neurotrophic factors (CNTF), glial cell line-
derived neurotrophic factor (GDNF), neurotrophin-3 (NT-
3) and neurotrophin 4/5 (NT-4/5).

10. The composition according to claim 9,
15 wherein said neurotrophic factor is nerve growth factor
(NGF).

Sub B1
20 11. A method for stimulating neuronal
regeneration in a patient or in an ex vivo nerve cell,
comprising the step of administering to said patient or
said nerve cell a compound according to any one of claims
1-6.

25 12. The method according to claim 11, wherein
said compound is administered to a patient and is
formulated together with a pharmaceutically suitable
carrier into a pharmaceutically acceptable composition.

30 13. The method according to claim 12,
comprising the additional step of administering to said
patient a neurotrophic factor either as part of a

multiple dosage form together with said compound or as a separate dosage form.

14. The method according to claim 13, wherein
5 said neurotrophic factor is selected from nerve growth factor (NGF), insulin-like growth factor (IGF-1) and its active truncated derivatives such as gIGF-1 and Des(1-3)IGF-I, acidic and basic fibroblast growth factor (aFGF and bFGF, respectively), platelet-derived growth
10 factors (PDGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factors (CNTF), glial cell line-derived neurotrophic factor (GDNF), neurotrophin-3 (NT-3) and neurotrophin 4/5 (NT-4/5).

15. The method according to claim 14, wherein
15 said neurotrophic factor is nerve growth factor (NGF).

16. The method according to claim 15, wherein
20 said method is used to treat a patient suffering from a disease selected from trigeminal neuralgia, glossopharyngeal neuralgia, Bell's Palsy, myasthenia gravis, muscular dystrophy, muscle injury, progressive muscular atrophy, progressive bulbar inherited muscular atrophy, herniated, ruptured, or prolapsed intervertebrae
25 disk syndrome's, cervical spondylosis, plexus disorders, thoracic outlet destruction syndromes, peripheral neuropathies, such as those caused by lead, dapsone, ticks, or porphyria, other peripheral myelin disorders, Alzheimer's disease, Gullain-Barre syndrome, Parkinson's
30 disease and other Parkinsonian disorders, ALS, Tourette's syndrome, multiple sclerosis, other central myelin disorders, stroke and ischemia associated with stroke,

20E010" 8686E00T

neural paropathy, other neural degenerative diseases,
motor neuron diseases, sciatic crush, neuropathy
associated with diabetes, spinal cord injuries, facial
nerve crush and other trauma, chemotherapy- and other
5 medication-induced neuropathies, and Huntington's
disease.

17. The method according to claim 16,
wherein said method is used to stimulate neuronal
10 regeneration in an ex vivo nerve cell.

18. The method according to claim 17,
comprising the additional step of contacting said ex
vivo nerve cell with a neurotrophic factor.
15

19. The method according to claim 18, wherein
said neurotrophic factor is selected from nerve growth
factor (NGF), insulin-like growth factor (IGF-1) and its
active truncated derivatives such as gIGF-1 and
20 Des(1-3)IGF-I, acidic and basic fibroblast growth factor
(aFGF and bFGF, respectively), platelet-derived growth
factors (PDGF), brain-derived neurotrophic factor (BDNF),
ciliary neurotrophic factors (CNTF), glial cell line-
derived neurotrophic factor (GDNF), neurotrophin-3 (NT-
25 3) and neurotrophin 4/5 (NT-4/5).

20. The method according to claim 19, wherein
said neurotrophic factor is nerve growth factor (NGF).

10039898.010302